Synapse Open Synapse
Biology

Lilly shuffles business structure; Novartis writes off part of Avidity deal

BioPharma Dive · · 2 min read

Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.

Latest from BioPharma Dive